APACHE Cohort (A Psoriatic Arthritis CoHort)
NCT03768271 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 425
Last updated 2026-04-27
Summary
Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease, belonging to the wide spectrum of spondyloarthritis, but with the particularity to be associated with personal psoriasis or familial psoriasis. PsA can be a very disabling disease through progressive and irreversible joint damage. Long-term functional prognosis of patients with PsA is correlated with the presence and severity of the radiographic joint lesions of the disease.
However, the proportion of patients who will develop those peripheral joint damages is not yet known and less over the factors which are associated/involved in such an aggressive pattern of the disease. Early identification of this subgroup of patients is particularly important for determining early "intensive" treatment, strict management with a Treat To Target approach, and identification of new treatments with a stronger structural effect.
The main objective of this prospective 10 years cohort is to describe the 5 years structural (radiographic) severity of recent Psoriatic arthritis (PsA)with recent peripheral arthritis.Some of the secondary objectives are to describe the 10 years structural severity within those patients, and to determine the predictive factors of those 5 and 10 years radiographic lesions (genetic, environmental, clinic, therapeutic factors).
APACHE will provide a unique longitudinal standardized database concerning patients with PsA with very recent peripheral arthritis. Research projects which will based on those collected data should allow to identify the mechanisms of aggressive joint damage, to highlight mew treatments targets, to better describe the burden of the disease, to test previous or develop new assessments tolls, to develop early diagnostic criteria
Conditions
- Cohort Study
- Psoriatic Arthritis (PsA)
- Recent Peripheral Arthritis
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Isabelle VIVALDO · DRCD-Assistance Publique des Hôpitaux de Paris
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-12
- Primary Completion
- 2031-12-01
- Completion
- 2036-12-01
Countries
- France
Study Locations
More Related Trials
-
Initial Standardized Global Review in Axial Spondyloarthritis
NCT07141017 ·Status: RECRUITING ·Phase: NA
-
Purify Antigen-specific B Cells From Patients With Rheumatoid Arthritis
NCT05203952 ·Status: UNKNOWN
-
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
NCT05516758 ·Status: TERMINATED ·Phase: PHASE2
-
SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
NCT05598684 ·Status: RECRUITING
-
Remission and Joint Damage Progression in Early Rheumatoid Arthritis
NCT00122382 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
NCT03783026 ·Status: COMPLETED ·Phase: PHASE4
-
Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis
NCT05082805 ·Status: UNKNOWN
-
Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis
NCT02885818 ·Status: COMPLETED
-
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
NCT02552212 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients
NCT01288287 ·Status: COMPLETED
-
A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis
NCT02627768 ·Status: COMPLETED
-
Single Dose PG102 in Patients With Active Psoriatic Arthritis
NCT00787137 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
NCT01500278 ·Status: COMPLETED ·Phase: PHASE4
-
Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases
NCT05026892 ·Status: UNKNOWN
-
Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia
NCT04806867 ·Status: COMPLETED
-
Tapering of Biologics in Inflammatory Arthritis Patients in Remission
NCT04429776 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS
NCT03632187 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Intestinal Microbiota Dysbiosis in the Development of Spondyloarthritis
NCT04853212 ·Status: RECRUITING ·Phase: NA
-
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
NCT03270501 ·Status: COMPLETED ·Phase: PHASE3
-
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
NCT01087762 ·Status: COMPLETED ·Phase: PHASE3
-
Papillomavirus Load in Rheumatic Inflammatory Diseases
NCT03713736 ·Status: UNKNOWN ·Phase: NA
-
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
NCT03662919 ·Status: COMPLETED
-
CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
NCT03953378 ·Status: COMPLETED
-
Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
NCT01845818 ·Status: COMPLETED
-
Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria
NCT01426815 ·Status: COMPLETED ·Phase: PHASE3